Uncategorized Archives - Page 13 of 157

FridayNov 14, 2025 10:00 am

Wegovy, Ozempic Could Reduce Deaths Resulting from Colon Cancer

A study that was recently published by a team of UC San Diego researchers has found that colon cancer patients who were also taking GLP-1 medications, such as Ozempic and Wegovy, had a 50% lower mortality rate when compared to colon cancer patients that didn’t use these medications. While these findings don’t suggest a causative effect, the researchers posit that the metabolic and anti-inflammatory effects of the GLP-1 drugs could be playing a role in reducing mortality among cancer patients. For their study, the team analyzed the medical records of at least 6,800 patients that had been diagnosed with colon…

FridayNov 14, 2025 9:45 am

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

Glioblastoma multiforme (“GBM”) is an aggressive brain cancer with limited treatment options, and CEO John Climaco emphasized the company’s commitment to overcoming the blood-brain barrier, a key obstacle in brain cancer therapy. Lead candidate TPI 287, an abeotaxane, has shown early evidence of appearing to cross the blood-brain barrier and producing clinical responses. Phase 2 planning is underway following encouraging data from a Phase 1 combination study with bevacizumab (Avastin). The company’s repurposed global clinical network and regulatory progress position it for potential late-stage development in 2026. TPI 287 holds multiple Orphan Drug Designations, covering gliomas, neuroblastoma, and other CNS-related…

ThursdayNov 13, 2025 11:15 am

HeartBeam Inc. (NASDAQ: BEAT) Advances Remote Cardiac Diagnostics with HeartNexus Partnership

Cardiovascular disease remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths annually. The HeartBeam System enables a patient to capture a 30-second ECG recording with its credit-card-sized, cable-free device, regardless of where they are. The HeartBeam-HeartNexus collaboration makes board-certified cardiologists available 24/7 to interpret the results for arrhythmia assessment and provide expert feedback directly to the patient or to a coordinating clinician. HeartBeam (NASDAQ: BEAT), a medical-technology company developing next-generation cardiac diagnostics via its patented 12-Lead ECG synthesis software, has announced a strategic collaboration with HeartNexus (https://ibn.fm/yyz1i). The partnership will expand access to cardiologist-level ECG insights for…

ThursdayNov 13, 2025 10:00 am

Rarest Natural Element Promises to Revolutionize How Cancer is Treated

Scientists at Texas A&M University have unlocked a new way that involves leveraging the rarest natural element, astatine-211, to kill cancer cells. This form of radiotherapy eliminates malignant cells while leaving the healthy tissues surrounding the cancer unaffected. One of the biggest challenges that have plagued conventional cancer therapies like chemotherapy and radiotherapy is that the treatments are indiscriminate and impact both cancerous tissues and healthy cells. As a result, these treatments cause side effects that can often be very serious or even life-threatening. The use of astatine-211 promises to address this drawback of existing radiotherapy approaches. Astatine (a Greek…

TuesdayNov 11, 2025 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Recognized as a Top Global Innovator in Portable ECG Technology

The company was ranked second worldwide out of 243 companies evaluated in 12-lead ECG innovation in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system. HeartBeam’s intellectual-property foundation is a major reason for its placement. HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report (https://ibn.fm/ZuLCr). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in…

ThursdayNov 06, 2025 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Groundbreaking ECG System

ECG data is necessary for the diagnosis of all cardiac arrhythmias in order to assess severity, implications and treatment options. HeartBeam is reporting that its 12-lead ECG synthesis software for arrhythmia assessment has been submitted to the U.S. Food and Drug Administration for 510(k) clearance. To enable smooth commercialization, the company is building the infrastructure needed to support widespread adoption. In the world of heart health, palpitations are common, with atrial fibrillation (“AF”) being one of the most typical sustained arrhythmias in adults (https://ibn.fm/8TSNY). HeartBeam (NASDAQ: BEAT) is on the verge of transforming how AF is detected and managed with…

TuesdayNov 04, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers

The financing initiatives underscore a disciplined approach to capital management at a critical stage for Soligenix. The company’s leadership has emphasized that this strengthened balance sheet allows Soligenix to focus on execution rather than financing. SNGX has outlined a timeline of catalysts extending through the end of 2026. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series of strategic capital initiatives, including a $7.5 million public offering (https://ibn.fm/QKXcv), the company now reports a cash…

MondayNov 03, 2025 12:45 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma

Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the clinical advancement of HyBryte(TM) (synthetic hypericin) and related therapies. These changes are timely given the complexities of CTCL and the evolving therapeutic landscape. The company’s decision to refresh its CTCL advisory team reflects a recognition that commercialization preparation in the CTCL space, evolving regulatory expectations and the need for robust trial designs demand expert insight. Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise…

MondayNov 03, 2025 12:00 pm

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”) Sapu-003 is an injectable formulation of Everolimus (Afinitor(R)), which aims to offer higher bioavailability and better efficacy than oral versions of the drug The trial is conducted alongside partners like the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon Sapu Nano, which is in the Sapu family of companies, which was through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently revealed the company’s first in-human clinical trial of Sapu-003. The announcement occurred at the Australian Translational Breast Cancer Research…

TuesdayOct 28, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C. Soligenix’s ThermoVax(R) technology has broad applicability in Emerging Infectious Disease. Current vaccines for Ebola and similar filoviruses face a major deployment barrier: Most require storage between 2°C and 8°C throughout transport, making them vulnerable to spoilage when exposed to the high ambient heat common in many outbreak regions (https://ibn.fm/MZWfk). Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, has published a peer-reviewed summary of new…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Wegovy, Ozempic Could Reduce Deaths Resulting from Colon Cancer

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

HeartBeam Inc. (NASDAQ: BEAT) Advances Remote Cardiac Diagnostics with HeartNexus Partnership

Rarest Natural Element Promises to Revolutionize How Cancer is Treated

HeartBeam Inc. (NASDAQ: BEAT) Recognized as a Top Global Innovator in Portable ECG Technology

HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Groundbreaking ECG System

Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers

Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search